Further positive data has been revealed on a drug that has been approved across North America in recent months for hereditary angioedema (HAE).
Ireland-headquartered company Shire (LSE: SHP), which is set to be taken over by Japanese drugmaker Takeda (TYO: 4502) early next year, won approval for Takhzyro (lanadelumab) in the USA in August and in Canada the following month.
The rare disease specialist is presenting further data on the subcutaneously administered treatment’s efficacy and safety in HAE at the American College of Allergy, Asthma & Immunology 2018 Annual Scientific Meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze